Abbott Laboratories
Abbott Laboratories Enters New Five-Year Revolving Credit Agreement
Summary
On January 29, 2024, Abbott Laboratories entered into a new Five-Year Revolving Credit Agreement, providing the company with the ability to borrow up to $5 billion on an unsecured basis. This agreement replaces an existing credit agreement, which was terminated on the same day. The new agreement will mature on the fifth anniversary of the effective date, and Abbott's borrowings will bear interest based on either a base rate or a SOFR rate, plus an applicable margin.
Profitelligence Alerts
Get alerts for ABT
Be first to know when Abbott Laboratories files with the SEC.
Filing Categories
Advertisement
About Abbott Laboratories
Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.
Official SEC Documents
Advertisement